News | Breast Density | September 20, 2019

Densityai software will be deployed in up to 24 breast cancer screening clinics across Germany

Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial

September 20, 2019 — Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast cancer screening clinics across Germany. These clinics will provide breast density measurements at point of care to identify women for supplemental breast cancer screening as part of the DIMASOS 2 Trial.

Prof. Sylvia H. Heywang-Köbrunner, M.D., head of Referenzzentrum Mammographie München, internationally recognized for her work in contrast-enhanced breast magnetic resonance imaging (MRI) and modern biopsy procedures, is using densitas densityai breast density measures to establish a supplemental ultrasound screening protocol in the DIMASOS 2 trial.

“Women with dense breasts are subject to the masking effect of mammographic density and its association with breast cancer risk. The objective of the DIMASOS 2 trial is to test whether combined mammography/ultrasound exams can improve early cancer detection and if this can feasibly and cost effectively be done in routine screening workflow,” said Heywang-Köbrunner.  “The unique ability of the Densitas software to analyze prior ‘for presentation’ mammograms from a wide range of mammography scanner vendor models is pivotal to this trial and is important for any practical clinical deployment.”

Densitas densityai delivers fully automated, standardized and reproducible breast density assessments from standard DICOM clinical use mammograms. Results from densitas densityai are generated by two distinct algorithms that decouple the breast density assessment into quantitative and qualitative scales in alignment with the American College of Radiology (ACR) Breast Imaging-Reporting and Data System (BI-RADS) 4th and 5th edition density classification systems. These results can be incorporated into breast cancer risk models to provide standardized and reproducible patient-specific risk estimates.

The artificial intelligence (AI)-driven Densitas densityai processes the same clinical use images that radiologists examine, enabling seamless picture archiving and communication system (PACS)-centric integrations and retrospective auditing capabilities of routinely archived exams. 

For more information: www.densitas.health


Related Content

News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
Subscribe Now